Non-Hodgkin's Lymphoma Bears Evidence of New Mutation

by Rathi Manohar on  November 3, 2010 at 7:20 PM Cancer News
RSS Email Print This Page Comment bookmark
Font : A-A+

Non-Hodgkin Lymphoma (NHL), in some patients, shows evidence of a genetic mutation that impacts the encoding of the receptor for B cell-activating factor (BAFF),according to an online paper.

This paper was published online on November 1 in the Journal of Experimental Medicine
 Non-Hodgkin's Lymphoma Bears Evidence of New Mutation
Non-Hodgkin's Lymphoma Bears Evidence of New Mutation

BAFF, a soluble protein needed for B cell survival and maturation, is elevated in the blood of some NHL patients and is associated with poor prognosis.

This BAFF-R mutation, identified by a team led by Anne Novak and Gail Bishop, generates a receptor that transmits stronger than normal signals, thus boosting B cell function.

Although present in fewer than 10% of the tumors analyzed in the study, this mutation provides further evidence of the importance of BAFF signaling in this dangerous malignancy.



Source: Eurekalert

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Chronic Lymphocytic Leukemia AIDS-HIV-Cancer Bone Marrow Transplantation 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive